Stephen Albert Johnston
Overview
Explore the profile of Stephen Albert Johnston including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
1820
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burton J, Vail D, Willcox J, Al-Nadaf S, Adrianowycz S, Biggs D, et al.
J Am Vet Med Assoc
. 2024 Nov;
:1-7.
PMID: 39579476
Objective: To determine the prevalence of undiagnosed malignant neoplasms in a cohort of healthy middle-aged to older dogs. Methods: Healthy, client-owned dogs between the ages of 5.5 and 11.5 years...
2.
Burton J, Johnston S, Vail D, Eickhoff J, Sykes K, Brown J, et al.
Vet Immunol Immunopathol
. 2023 Dec;
267:110691.
PMID: 38056066
Preventative anti-cancer vaccination strategies have long been hampered by the challenge of targeting the diverse array of potential tumor antigens, with successes to date limited to cancers with viral etiologies....
3.
Shen L, Brown J, Johnston S, Altan M, Sykes K
J Transl Med
. 2023 May;
21(1):338.
PMID: 37217961
Purpose: To evaluate a new class of blood-based biomarkers, anti-frameshift peptide antibodies, for predicting both tumor responses and adverse immune events to immune checkpoint inhibitor (ICI) therapies in advanced lung...
4.
Shen L, Zhao Z, Lainson J, Brown J, Sykes K, Johnston S, et al.
RSC Adv
. 2022 May;
10(50):29675-29681.
PMID: 35518269
Parallel measurement of large numbers of antigen-antibody interactions are increasingly enabled by peptide microarray technologies. Our group has developed an synthesized peptide microarray of >400 000 frameshift neoantigens using mask-based...
5.
Peterson M, Murphy S, Lainson J, Zhang J, Shen L, Diehnelt C, et al.
BMC Immunol
. 2020 May;
21(1):25.
PMID: 32370785
Background: It is widely hoped that personal cancer vaccines will extend the number of patients benefiting from checkpoint and other immunotherapies. However, it is clear creating such vaccines will be...
6.
Shen L, Zhang J, Lee H, Batista M, Johnston S
Sci Rep
. 2020 Apr;
10(1):6251.
PMID: 32253381
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
7.
Stafford P, Johnston S, Kantarci O, Zare-Shahabadi A, Warrington A, Rodriguez M
PLoS One
. 2020 Mar;
15(3):e0229080.
PMID: 32196507
Therapeutic monoclonal antibodies have the potential to work as biological therapeutics. OKT3, Herceptin, Keytruda and others have positively impacted healthcare. Antibodies evolved naturally to provide high specificity and high affinity...
8.
Shen L, Zhang J, Lee H, Batista M, Johnston S
Sci Rep
. 2019 Nov;
9(1):17815.
PMID: 31767927
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
9.
Wang L, Whittemore K, Johnston S, Stafford P
Sci Rep
. 2019 Nov;
9(1):17645.
PMID: 31754184
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
10.
Shen L, Zhang J, Lee H, Batista M, Johnston S
Sci Rep
. 2019 Oct;
9(1):14184.
PMID: 31578439
The success of checkpoint inhibitors in cancer therapy is largely attributed to activating the patient's immune response to their tumor's neoantigens arising from DNA mutations. This realization has motivated the...